Tirzepatide Oral Dropsyog ib qho kev tsim kho tshiab uas tsis yog- txhaj tshuaj, nrog nws cov khoom xyaw tseem ceeb, tirzepatide, ua dual -action GLP-1/GIP receptor agonist. Piv nrog rau cov tshuaj txhaj tshuaj ib txwm siv, cov tshuaj hauv qhov ncauj tau nqus los ntawm sublingual mucosa, hla thawj - dhau qhov cuam tshuam ntawm lub plab zom mov thiab ncaj qha nkag mus rau cov ntshav ncig, yog li txhim kho bioavailability ntawm cov tshuaj. Qhov kev tsim no tsis tsuas yog ua kom yooj yim rau txoj kev tswj hwm tshuaj tab sis kuj tseem txhim kho kev siv tshuaj rau cov neeg mob, tshwj xeeb tshaj yog cov neeg ntshai lossis tsis yooj yim nrog kev txhaj tshuaj. Tirzepatide qhov ncauj tee feem ntau yog siv ib zaug ib hnub, thiab cov koob tshuaj tuaj yeem ua tus kheej raws li cov kev xav tau tshwj xeeb thiab kev zam ntawm tus neeg mob. Lub compact thiab portable formulation tsim tso cai rau cov neeg mob nqa nws nrog lawv thiab siv nws txhua lub sij hawm, ntxiv txhim khu kev yooj yim thiab ua raws li kev kho mob. Los ntawm tib lub sijhawm ua kom GLP-1 (glucagon-zoo li peptide-1) thiab GIP (glucose-dependent insulinotropic polypeptide) receptors, nws ua rau muaj ntau yam teebmeem ntawm lub cev, tswj cov ntshav qabzib thiab lub cev hnyav.
Peb cov khoom
Tirzepatide COA
Qhov zoo ntawm kev xa tshuaj mucosal thiab qhov tsim nyog ntawm kev tsim Tirzepatide Oral drops
Lub ntiaj teb no comorbidity tus nqi ntawm cov kab mob metabolic (hom 2 mob ntshav qab zib mellitus, rog rog) thiab kev puas siab puas ntsws (kev ntxhov siab, kev nyuaj siab) tau tshaj 30%, ua ib qho kev sib koom ua ke ntawm "kev puas siab ntsws metabolic". Cov kev kho mob ib txwm muaj cov kev txwv tseem ceeb: GLP-1 receptor agonists (xws li semaglutide) tuaj yeem tswj cov ntshav qab zib thiab qhov hnyav, tab sis yuav tsum tau txhaj tshuaj txhua lub lim tiam, ua rau cov neeg mob ua raws li cov neeg mob tsawg; Antidepressants tuaj yeem ua rau muaj kev cuam tshuam metabolic xws li qhov hnyav nce. Nyob rau hauv cov ntsiab lus no, mucosal tshuaj xa cov tshuab tau dhau los ua cov thev naus laus zis tseem ceeb rau kev tawg los ntawm kev kho cov fwj dej vim lawv qhov tshwj xeeb pharmacokinetic zoo.Tirzepatide Oral drops, raws li lub ntiaj teb thawj GLP-1 / GIP dual receptor agonist, tsis tsuas yog sawv cev rau kev tsim kho tshiab hauv kev siv tshuaj xa khoom, tab sis kuj tseem ua rau muaj kev hloov pauv hauv kev kho kab mob metabolic los ntawm "ib lub hom phiaj" mus rau "multimodal network tswj".
Lub ntsiab kom zoo dua ntawm mucosal tshuaj xa system: breakthroughs los ntawm lub cev mus rau pharmacokinetics
Lub qhov ncauj mucosa yog tsim los ntawm non keratinized stratified squamous epithelium, nrog ib tug tuab ntawm tsuas yog 0.5-0.8mm, ntau thinner tshaj ntawm daim tawv nqaij (1.5-4mm), thiab tsis muaj lub ntsiab nqus barrier ntawm lub stratum corneum. Lub sublingual mucosa yog tshwj xeeb tshaj yog tshwj xeeb, nrog ib tug nplua nuj network ntawm capillaries hauv qab nws. Cov tshuaj tuaj yeem nkag mus rau hauv cov hlab ntsha ncaj qha los ntawm kev sib kis, tsis txhob cuam tshuam thawj zaug. Piv txwv li, sublingual nitroglycerin ntsiav tshuaj tuaj yeem txo angina hauv 3 feeb tom qab tau nqus los ntawm cov mucosa, nrog rau bioavailability ntawm 80%, thaum lub qhov ncauj formulations muaj ib tug bioavailability ntawm tsawg tshaj li 10% vim thawj dhau los. Tirzepatide muaj ib qho hnyav molecular ntawm 53 kDa thiab belongs rau chav kawm ntawm macromolecular peptide tshuaj. Cov kev cai ntawm qhov ncauj tau yooj yim degraded los ntawm plab hnyuv enzymes thiab nyuaj rau nkag mus rau hauv plab hnyuv mucosa. Los ntawm kev tswj hwm sublingual, nws cov bioavailability tuaj yeem nce mus rau 40-60% ntawm qhov kev txhaj tshuaj, zoo dua li qhov ncauj semaglutide (1-2%). Txoj kev tshawb fawb SURPADS-MIND tau pom tias cov neeg mob nyob hauvTirzepatide qhov ncauj tee15mg koob tshuaj pab pawg poob qhov nruab nrab ntawm 21% qhov hnyav thiab 2.58% HbA1c hauv 52 lub lis piam, uas yog piv rau cov txiaj ntsig ntawm kev txhaj tshuaj. Txawm li cas los xij, qhov tshwm sim ntawm kev mob plab hnyuv tau txo qis los ntawm 15%.
Pharmacokinetic zoo: pib sai thiab meej kev cai
Txoj kev xa tshuaj mucosal ua tiav cov kev cai ntawm lub cev thiab qhov chaw ntawm kev siv tshuaj los ntawm "hauv zos central" dual channel. Thaum lub sij hawm ua hauj lwm hauv zos, cov tshuaj tsim cov tshuaj reservoir rau ntawm qhov chaw ntawm lub qhov ncauj mucosa thiab raug tso tawm tsis tu ncua mus rau hauv txoj hnyuv. Tirzepatide activates GLP-1 receptors hauv sublingual mucosa, inhibits salivary amylase secretion, thiab txo cov ntshav qabzib hloov pauv tom qab; Nyob rau tib lub sijhawm, kev ua haujlwm ntawm GIP receptors txhawb kev zais ntawm mucin los ntawm qhov ncauj submucosal qog, tsim kev tiv thaiv kev tiv thaiv thiab txo cov tshuaj tiv thaiv. Cov tshuaj bypasses cov ntshav-hlwb barrier los ntawm cov hlab ntsha sublingual thiab ncaj qha ua rau lub hypothalamic arcuate nucleus thiab limbic system. Cov kev tshawb fawb FMRI tau pom tias tom qab 12 lub lis piam ntawm kev kho mob, kev sib txuas ua haujlwm ntawm amygdala thiab prefrontal cortex ntawm cov neeg mob tau txhim kho, kev tswj lub siab lub ntsws muaj peev xwm txhim kho los ntawm 25%, thiab tus qhab nia ntawm Tus Kheej Kev ntxhov siab (SAS) qhab nia raug txo los ntawm 30%.
Cov tshuaj txhaj tshuaj ib txwm xav tau kev ua haujlwm tshaj lij thiab raug kev txom nyem los ntawm koob ntshai teeb meem, thaum lub tshuab xa tshuaj mucosal ua tiav "kev tswj hwm tus kheej" los ntawm sublingual tee. Tirzepatide Drops siv microfluidic thev naus laus zis los npaj nanoscale tee nrog qhov tseeb ntawm 0.1mg, txhawb kev hloov kho gradient los ntawm 2.5mg mus rau 15mg. Cov ntaub ntawv kho mob qhia tau hais tias cov neeg mob muaj kev lees txais ntawm 92% rau qhov ncauj tee, ntau dua li 68% rau kev txhaj tshuaj. Tsis tas li ntawd, qhov ncauj tee tsis tas yuav tsum tau khaws cia hauv tub yees, ua rau lawv yooj yim rau kev thauj mus los thiab siv tau ntev, tshwj xeeb tshaj yog tsim rau cov peev txheej txwv.
Qhov tsim nyog ntawm kev tsim Tirzepatide Qhov ncauj tee: los ntawm cov kev tsis sib haum xeeb mus rau qhov kev xav tau ntawm kev kho mob
Txawm hais tias mucosal tshuaj xa cov tshuab muaj txiaj ntsig zoo, qhov kev nqus ntawm cov tshuaj peptide loj molecule tseem ntsib cov enzymatic degradation. Cov qaub ncaug ntawm qhov ncauj muaj amylase, protease, thiab lwm yam, uas tuaj yeem ua rau cov peptide daim ntawv cog lus ntawm Tirzepatide. Pab neeg R&D siv cyclodextrin inclusion technology los encapsulate cov tshuaj molecules nyob rau hauv lub - cyclodextrin kab noj hniav, tsim ib tug enzyme tiv thaiv barrier uas ua rau kom cov stability ntawm cov tshuaj nyob rau hauv qaub ncaug ntau tshaj 90%. Cov kev pom ib txwm muaj yog tias cov tshuaj uas muaj qhov hnyav molecular tshaj 500 Da yog qhov nyuaj rau nkag mus rau hauv mucosa. Tirzepatide siv lipid nanoparticles (LNP) ua tus nqa khoom kom txo tau txoj kab uas hla ntawm cov molecule mus rau 80nm, thaum txuas lub sij hawm tuav cov mucosal los ntawm kev hloov kho saum npoo nrog polyethylene glycol (PEG), uas ua rau muaj peb npaug ntawm kev nqus tau zoo. Kev tswj hwm mucosal raug cuam tshuam rau yam xws li qaub ncaug ntws thiab nqos txav. Pab pawg R&D tau tsim ib qho kev txawj ntse txhawb nqa- tso tawm thaj, uas tswj cov tshuaj tso tawm tus nqi los ntawm qhov kub thiab txias hydrogel kom ntseeg tau tias qhov sib txawv ntawm cov ntshav cov tshuaj concentration hauv 24 teev tsawg dua 15%.
Clinical Needs: Cov Kev Xav Tau Tsis Txaus Siab rau Metabolic Emotional Comorbidity
Lub comorbidity mechanism ntawm cov kab mob metabolic thiab kev puas siab puas ntsws cuam tshuam nrog kev sib cuam tshuam ntawm "lub hlwb lub hlwb" thiab "hypothalamic pituitary adrenal axis (HPA axis)". Inflammatory yam secreted los ntawm cov ntaub so ntswg adipose nyob rau hauv cov neeg mob rog rog, xws li IL-6 thiab TNF - , tuaj yeem nkag mus rau hauv cov hlab ntsha-hlwb barrier, qhib microglia, ua rau hippocampal neuronal apoptosis, thiab ua rau muaj kev nyuaj siab zoo li tus cwj pwm. Tirzepatide tuaj yeem txo qis cytokine theem ntawm 30% thiab thim rov qab hippocampal ntim atrophy los ntawm kev poob ntau dua 15%. Kev ntxhov siab hauv lub xeev ua rau HPA axis, ua rau muaj kev nce hauv cortisol, insulin tsis kam, thiab cov rog hauv plab. Tirzepatide txo cov qib cortisol los ntawm 25% thiab txhim kho insulin rhiab heev los ntawm kev tswj cov haujlwm ntawm hypothalamic CRH neurons.
Kev kho mob ib txwm xav tau kev sib xyaw ua ke ntawm GLP-1 receptor agonists thiab tshuaj tiv thaiv kev ntxhov siab, tab sis muaj kev pheej hmoo ntawm kev cuam tshuam tshuaj. Tirzepatide Oral drops tswj GLP{10}}1/GIP receptors ib txhij los ntawm ib qho molecule, ua tiav kev tswj hwm synchronous ntawm "metabolism siab" dual txoj kev. SURPASS-MIND subgroup tsom xam pom tias tom qab 15mg koob tshuaj tau siv rau hauv cov neeg mob ntshav qab zib hom 2 uas muaj kev ntxhov siab, HbA1c poob los ntawm 2.3%, lub cev qhov hnyav poob los ntawm 19%, thiab HAM-A kev ntxhov siab qhov qhab nia poob los ntawm 40%. Cov nyhuv tau zoo dua li ntawm pawg kho mob ua ke.
Kev Ua Lag Luam Muaj Peev Xwm: Lub Sijhawm rau Kev Hloov Pauv hauv Ntiaj Teb Metabolic Disease Treatment Market
Kev lag luam thoob ntiaj teb loj rau kev kho cov kab mob metabolic xav tias yuav ncav cuag $ 1.2 trillion los ntawm 2030, nrog rau qhov feem pua ntawm qhov ncauj npaj tau nce los ntawm 15% mus rau 40%.Tirzepatide Oral Drops, nrog rau nws qhov zoo ntawm tsis yog -kev tswj hwm kev tswj hwm, lub hom phiaj ob lub hom phiaj, thiab kev siv tus kheej, xav tias yuav dhau los ua thawj cov tshuaj metabolic hauv qhov ncauj nrog kev muag khoom txhua xyoo ntau dua $ 20 billion. Raws li daim ntawv tshaj tawm nyiaj txiag xyoo 2025 ntawm Eli Lilly, cov khoom lag luam tau ua tiav Phase III kev sim tshuaj ntsuam xyuas thiab xav tias yuav tau txais kev pom zoo rau kev lag luam tawm hauv Q2 2026, nrog rau kev lag luam thaum ntxov ntawm 35%.
Cim npe nrov: Tuam Tshoj tirzepatide qhov ncauj drops manufacturers, lwm tus neeg
